Jefferies maintained its Buy rating on Verastem, Inc. (VSTM) on March 05, 2026, citing a “catalyst-rich 2026.” The VSTM analyst rating was reiterated amid launch progress and revenue growth signals. Jefferies also kept a $19.00 price target, per Investing.com, and StreetInsider reported the note on March 05, 2026. Meyka AI rates VSTM with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

VSTM analyst rating: Jefferies reiteration on March 05, 2026

Jefferies reiterated Buy on Verastem (VSTM) on March 05, 2026.
The firm cited launch momentum and a pipeline of catalysts as reasons to hold the rating.
Jefferies kept a $19.00 price target, according to Investing.com source.
StreetInsider also published the Jefferies note the same day source.

VSTM analyst rating: catalysts Jefferies highlights

Jefferies points to a “catalyst-rich 2026” driven by launch execution.
The analyst referenced Q4 2025 revenue gains and adoption signals after the May 2025 approval.
Jefferies notes pipeline milestones, including mid-2027 readouts for key trials, as upside drivers for Verastem.

VSTM analyst rating: what the reiteration means for investors

A maintained Buy means Jefferies sees upside but expects execution risk.
Investors should view the rating as confidence in growth, not a guaranteed outcome.
The reaffirmation suggests analysts expect revenue to keep improving and trial milestones to re-rate the stock.

VSTM analyst rating: historical coverage and price targets

Jefferies remains the notable active analyst on VSTM in this cycle.
The firm’s $19.00 price target gives investors a concrete valuation anchor.
Prior coverage has oscillated between cautious Buy calls and Hold views as clinical and launch data arrived.

VSTM market context, stock moves, and metrics

Verastem’s market cap stands at $372,311,535.
The stock moved 0.33% ($0.02) on the Jefferies note, reflecting modest investor response.
Investors should weigh valuation against pipeline risk and recent 34% revenue growth over the last twelve months.

Meyka AI view and next steps for VSTM investors

Meyka AI rates VSTM with a grade of B+ based on benchmark comparison and analyst consensus.
We recommend monitoring trial milestones, quarterly launch metrics, and cash runway.
For real-time updates, see the Meyka stock page for VSTM at Meyka VSTM.

Final Thoughts

Jefferies’ March 05, 2026 reiteration of a Buy on Verastem, Inc. (VSTM) keeps analyst sentiment positive ahead of key 2026 catalysts. The maintained rating and the $19.00 price target signal belief in continuing revenue momentum and milestone-driven upside. For investors, the note is a green light to watch execution closely rather than a prompt for immediate heavy buying. The reaffirmation reduces uncertainty about analyst conviction, but it does not remove clinical or launch risk. Short-term stock moves were muted, with a 0.33% ($0.02) change on the note, suggesting the market had partially priced in the update. Given Verastem’s market cap of $372,311,535 and recent 34% revenue growth, a maintained Buy from Jefferies supports a cautiously optimistic view. Remember, Meyka AI rates VSTM with a grade of B+, which factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.